Habib Dable, MBA

Advisor

Habib Dable is an Advisor at Raven, where he supports new companies, portfolio companies, and executives. He brings more than 30 years of leadership experience across large pharmaceutical companies and emerging biotechnology companies. He serves on the boards of Atavistik Bio, Tyra Biosciences, SpyGlass Pharma, Relay Therapeutics, and PepGen.

Previously, Habib spent five years as President and Chief Executive Officer of Acceleron Pharma. He led its growth into a commercial-stage company, including the launch of REBLOZYL®, before its acquisition by Merck in 2021. Earlier, he spent 22 years at Bayer AG in roles of increasing responsibility, including President of U.S. Pharmaceuticals and Global Head of Specialty Medicine. He also led the global launch of EYLEA®.

Habib earned a BBA in Marketing and Finance and an MBA in International Business from the University of New Brunswick. He completed executive programs at Stanford Graduate School of Business and Korn Ferry and holds a Director Professionalism® Certificate from the National Association of Corporate Directors.